Low-Level Light Therapy

Low-level light therapy • Technical information

How LLLT works for dry eye

A detailed guide to low-level light therapy for patients considering treatment for dry eye linked to meibomian gland dysfunction.

At a glance

Type
Photobiomodulation using light-emitting diodes (LEDs), not a laser.
Light
Red light, commonly around 633 nm.
Target
Eyelids and meibomian glands.
Role
One option within a broader dry-eye management plan.

The underlying problem

Meibomian gland dysfunction

The tear film has three layers. The outer oily layer is produced by the meibomian glands, which sit inside the upper and lower eyelids and open along the lid margin. This oil slows evaporation and keeps the tear film stable between blinks.

In meibomian gland dysfunction (MGD), the oil becomes thicker and the gland openings can block. Less oil reaches the tear film, tears evaporate faster and the eye surface becomes irritated. Inflammation of the lid margin can then worsen gland function, creating an ongoing cycle.

MGD is one of the most common contributors to evaporative dry eye. Over time, untreated glands may shrink or drop out, which is why early assessment matters.

Healthy meibomian glands compared with blocked glands Healthy Blocked (MGD) Oil reaches the tear film Thick oil blocks openings Some glands shrink or drop out Stable oil layer
Meibomian glands inside the eyelid, ending at the lid margin.

Mechanism

What the light does

LLLT is a form of photobiomodulation: low-intensity light used to influence cell activity without damaging tissue. The proposed effects work together.

LED mask Emits low-intensity red light
→
Eyelid tissue Light passes into the lid
→
Mitochondria Absorb the light energy
→
Gland response Energy up, inflammation down

Cellular energy

Red light is absorbed by cytochrome c oxidase, an enzyme in the mitochondria. This is thought to increase cellular energy (ATP) production and support gland cell function.

Inflammation

Photobiomodulation is associated with reduced inflammatory signalling and oxidative stress in treated tissue, which may help calm the lid margin.

Gentle warming

The mask produces mild, even warmth across the eyelids. Warmth helps soften thickened oil so it flows more easily from the glands.

The evidence

What research shows so far

Published clinical studies of LLLT for dry eye have reported improvements in measures such as tear break-up time, tear film lipid layer thickness, meibum quality and symptom scores after a short course of treatment.

  • A randomised, observer-masked trial found improvements in ocular surface staining, tear production and upper-lid meibography compared with a sham treatment.1
  • A prospective study using 633 nm light found improvements in tear stability, lipid layer thickness and symptom scores across three weekly sessions.2
  • A case series reported resolution of persistent chalazia after LLLT, although evidence for recurrent styes is limited to small studies.3
  • Reviews describe a favourable safety profile, with no serious ocular adverse events reported in published trials.4

The evidence base is still developing. Many studies are small, use different devices and settings, and follow patients for weeks rather than years. Results vary between individuals, and LLLT is generally used alongside other dry-eye care rather than as a stand-alone cure.

Suitability

Who may benefit

  • Evaporative dry eye linked to MGD
  • Ongoing symptoms despite lid hygiene and drops
  • Recurrent lid margin inflammation
  • Contact lens discomfort related to MGD
  • Recurrent styes or chalazia

Precautions

We consider the following when assessing whether LLLT is suitable:

  • Light sensitivity or photosensitive skin conditions
  • Epilepsy or light-triggered migraine
  • Photosensitising medicines, such as isotretinoin
  • Pregnancy
  • Recent eye or eyelid surgery
  • Active eye or skin infection near the eyes

The procedure

What happens during a session

1

Suitability check

Your optometrist reviews your eye findings, medical history and medicines before the first session.

2

Preparation

Makeup and skincare are removed from around the eyes. Contact lenses come out before treatment.

3

Positioning

You sit back comfortably with your eyes closed while the LED mask is fitted over the eye area.

4

Light session

The mask delivers red light and gentle warmth, typically for around 15-20 minutes.

5

Gland expression

If indicated, gentle pressure on the eyelids clears softened oil from the glands.

6

Aftercare

Brief warmth or redness may follow. Your optometrist will advise on ongoing lid care.

Measuring progress

How we track your response

Objective measurements before and during a course of treatment show whether LLLT is helping and guide what comes next.

Symptom questionnaire

A standardised score of dryness, discomfort and impact on daily activities.

Tear break-up time

How long the tear film stays stable after a blink.

Meibum quality

The appearance and flow of oil expressed from the glands.

Gland imaging

Meibography shows the structure of the glands inside the eyelids.

Ocular surface staining

A dye highlights areas of surface dryness or damage.

Lid margin examination

Signs of blocked gland openings and inflammation.

Technical questions

Frequently asked questions

Is LLLT a laser?

No. It uses LEDs at low intensity. The light does not cut or burn tissue.

Is the light safe for my eyes?

Your eyes stay closed under the mask, and the light is directed at the eyelids. Tell us if the light or warmth feels uncomfortable.

Why is more than one session needed?

Photobiomodulation effects build over repeated exposure. Studies typically use a short course spaced about a week apart.

How long do the effects last?

Long-term data is limited. Some patients need maintenance sessions, which your optometrist will discuss based on your results.

Does it replace eye drops or lid care?

Usually not. LLLT works best as part of a plan that may include lid hygiene, warm compresses and lubricating drops.

Can it be combined with other treatments?

Yes. LLLT is often used with gland expression or zest treatments, depending on your findings.

References

  1. Park Y, et al. Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial. Scientific Reports. 2022. Link
  2. Antwi A, et al. Effect of low-level light therapy in individuals with dry eye disease. Ophthalmic and Physiological Optics. 2024. Link
  3. Stonecipher K, et al. Low level light therapy for the treatment of recalcitrant chalazia: a sample case summary. Clinical Ophthalmology. 2019. Link
  4. Low-level light therapy promising for dry eye disease management. Healio Optometry. 2026. Link
← Back to dry eye assessment